BioCentury | Nov 7, 2019
Politics & Policy

Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity

...share to Descovy, which has a more favorable adverse event profile. Steve Usdin, Washington Editor Gilead Sciences Inc. Mylan Inc. Teva...
BioCentury | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...TP-434) Zulresso, brexanolone (sage-547) AbCellera AbCellera Biologics Inc. Amgen Amgen Inc. Blueprint Medicines Blueprint Medicines Corp. Celgene Celgene Corp. Gilead Gilead Sciences Inc. Intra-Cellular Intra-Cellular Therapies Inc. Les Laboratoires Servier Mylan Mylan Inc. OncoMed OncoMed...
BioCentury | Jun 22, 2018
Clinical News

FDA approves Suboxone generics from Mylan, Dr. Reddy

..."Gottlieb Unveils Guidance for Opioid Dependence Treatments" ). Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Mylan Inc....
BioCentury | Jun 4, 2016
Clinical News

Mylan/Biocon biosimilar shows equivalence to Herceptin

Mylan Inc. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said Myl-1401O, their biosimilar of Herceptin trastuzumab, met the primary endpoint of bioequivalence to its reference product in the Phase III HERITAGE study, which compared the...
BioCentury | Mar 28, 2016
Company News

Acorda, AstraZeneca, Mylan Inc. endocrine/metabolic, autoimmune news

...BioCentury, March 21). Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Mylan Inc....
BioCentury | Apr 17, 2015
Top Story

FDA approves first generic Copaxone

...of Copaxone will launch in September. An ANDA for a generic version of Copaxone from Mylan Inc....
BioCentury | Mar 2, 2015
Company News

Amgen, Bayer, Mylan Inc. generics news

...EUR773 million ($939.6 million). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Mylan Inc....
BioCentury | Feb 9, 2015
Company News

Theravance Biopharma, Mylan deal

...not respond to requests for more information. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Mylan Inc....
BioCentury | Feb 9, 2015
Analyst Picks & Changes

Analyst picks & changes

...$17.44 Skorney also raised his target to $17 from $13 after Theravance Biopharma partnered with Mylan Inc....
BioCentury | Feb 3, 2015
Company News

Theravance Biopharma, Mylan strike COPD deal

...Theravance Biopharma Inc. (NASDAQ:TBPH) and Mylan Inc. (NASDAQ:MYL) entered a development and commercialization agreement for nebulized TD-4208...
Items per page:
1 - 10 of 266
BioCentury | Nov 7, 2019
Politics & Policy

Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity

...share to Descovy, which has a more favorable adverse event profile. Steve Usdin, Washington Editor Gilead Sciences Inc. Mylan Inc. Teva...
BioCentury | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...TP-434) Zulresso, brexanolone (sage-547) AbCellera AbCellera Biologics Inc. Amgen Amgen Inc. Blueprint Medicines Blueprint Medicines Corp. Celgene Celgene Corp. Gilead Gilead Sciences Inc. Intra-Cellular Intra-Cellular Therapies Inc. Les Laboratoires Servier Mylan Mylan Inc. OncoMed OncoMed...
BioCentury | Jun 22, 2018
Clinical News

FDA approves Suboxone generics from Mylan, Dr. Reddy

..."Gottlieb Unveils Guidance for Opioid Dependence Treatments" ). Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Mylan Inc....
BioCentury | Jun 4, 2016
Clinical News

Mylan/Biocon biosimilar shows equivalence to Herceptin

Mylan Inc. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said Myl-1401O, their biosimilar of Herceptin trastuzumab, met the primary endpoint of bioequivalence to its reference product in the Phase III HERITAGE study, which compared the...
BioCentury | Mar 28, 2016
Company News

Acorda, AstraZeneca, Mylan Inc. endocrine/metabolic, autoimmune news

...BioCentury, March 21). Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Mylan Inc....
BioCentury | Apr 17, 2015
Top Story

FDA approves first generic Copaxone

...of Copaxone will launch in September. An ANDA for a generic version of Copaxone from Mylan Inc....
BioCentury | Mar 2, 2015
Company News

Amgen, Bayer, Mylan Inc. generics news

...EUR773 million ($939.6 million). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Mylan Inc....
BioCentury | Feb 9, 2015
Company News

Theravance Biopharma, Mylan deal

...not respond to requests for more information. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Mylan Inc....
BioCentury | Feb 9, 2015
Analyst Picks & Changes

Analyst picks & changes

...$17.44 Skorney also raised his target to $17 from $13 after Theravance Biopharma partnered with Mylan Inc....
BioCentury | Feb 3, 2015
Company News

Theravance Biopharma, Mylan strike COPD deal

...Theravance Biopharma Inc. (NASDAQ:TBPH) and Mylan Inc. (NASDAQ:MYL) entered a development and commercialization agreement for nebulized TD-4208...
Items per page:
1 - 10 of 266